The ability of the PI3K/AKT/CDK4 signaling pathway to hinder the growth, movement, and programmed cell death of ovarian cancer cells establishes a solid basis for further investigation and potential use in the management of ovarian cancer. This evidence concerns the gene CDK4 and ovarian cancer.